Avrahami Daniel, Hammond Amanda, Higgins Ceara, Vernon Howard
Toronto, ON, Canada.
Chiropr Man Therap. 2012 Mar 21;20:7. doi: 10.1186/2045-709X-20-7.
To investigate the effects of topical agents for the treatment of Myofascial Pain Syndrome (MPS) and Myofascial Trigger Point (MTRP).
Subjects with an identifiable trigger point in the trapezius muscle, age 18-80 were recruited for a single-session randomized, placebo-blinded clinical study. Baseline measurements of trapezius muscle pressure pain threshold (PPT: by pressure algometer) along with right and left cervical lateral flexion (rangiometer) were obtained by a blinded examiner. An assessor blinded to the outcomes assessments applied one of 6 topical formulations which had been placed in identical plastic containers. Five of these topicals were proposed active formulations; the control group was given a non-active formulation (PLA). Five minutes after the application of the formula the outcome measures were re-tested. Data were analyzed with a 5-way ANOVA and Holms-adjusted t-tests with an alpha level of 0.05.
120 subjects were entered into the study (63 females; ages 16-82); 20 subjects randomly allocated into each group. The pre- and post-treatment results for pressure threshold did show significant intra-group increases for the Ben-Gay Ultra Strength Muscle Pain Ointment (BG), the Professional Therapy MuscleCare Roll-on (PTMC roll-on) and Motion Medicine Cream (MM) with an increased threshold of 0.5 kg/cm2 (+/-0.15), 0.72 kg/cm2 (+/-0.17) and 0.47 Kg/cm2 (+/-0.19) respectively. With respect to the inter-group comparisons, PTMC roll-on showed significant increases in pressure threshold compared with Placebo (PLA) (p = 0.002) and Icy Hot Extra Strength Cream (IH) (p = 0.006). In addition, BG demonstrated significant increases in pressure threshold compared with PLA (p = 0.0003).
With regards to pressure threshold, PTMC roll-on, BG and MM showed significant increases in pain threshold tolerance after a short-term application on a trigger points located in the trapezius muscle. PTMC roll-on and BG were both shown to be superior vs placebo while PTMC was also shown to be superior to IH in patients with trigger points located in the trapezius muscle on a single application.CMCC Research Ethics Board Approval # 1012X01, 2011.
研究局部用药治疗肌筋膜疼痛综合征（MPS）和肌筋膜触发点（MTRP）的效果。
招募年龄在18 - 80岁、斜方肌有可识别触发点的受试者，进行单疗程随机、安慰剂对照的临床研究。由一位不知情的检查者使用压力痛觉计测量斜方肌压力疼痛阈值（PPT），并用角度计测量左右颈椎侧屈度，作为基线测量。一位对结果评估不知情的评估者应用6种置于相同塑料容器中的局部用药配方之一。其中5种局部用药为活性配方；对照组给予非活性配方（PLA）。用药5分钟后重新测试结果指标。数据采用五因素方差分析和Holms校正t检验进行分析，α水平设定为0.05。
120名受试者进入研究（63名女性；年龄16 - 82岁）；每组随机分配20名受试者。压力阈值的治疗前和治疗后结果显示，对于超强型Ben - Gay肌肉止痛软膏（BG）、专业治疗肌肉护理滚珠剂（PTMC滚珠剂）和运动医学乳膏（MM），组内压力阈值有显著升高，分别升高了0.5 kg/cm²（±0.15）、0.72 kg/cm²（±0.17）和0.47 Kg/cm²（±0.19）。在组间比较中，PTMC滚珠剂与安慰剂（PLA）相比，压力阈值显著升高（p = 0.002），与超强型冰热乳膏（IH）相比也显著升高（p = 0.006）。此外，BG与PLA相比，压力阈值显著升高（p = 0.0003）。
就压力阈值而言，PTMC滚珠剂、BG和MM在短期应用于斜方肌触发点后，疼痛阈值耐受性显著提高。在斜方肌有触发点的患者中，单次应用时，PTMC滚珠剂和BG均显示优于安慰剂，且PTMC也优于IH。CMCC研究伦理委员会批准号# 1012X01，2011年。
